丝源蛋白-4与赋形剂对照治疗中重度干眼症患者:一项随机临床试验
这项探索性2期、多中心、双盲、随机、赋形剂对照研究评估了丝源蛋白4(SDP-4,即amlisimod)滴眼液治疗中重度干眼症的安全性和有效性。第一队列305例患者按1:1:1:1随机接受SDP-4(0.1%、1%、3% w/w)或赋形剂每日两次,第二队列151例患者按1:1随机接受1% SDP-4或赋形剂每日两次。SDP-4(1%)在第一队列第28天和第56天显著增加TBUT(P<.05),第84天SANDE VAS评分较基线降低46%。
要点
- SDP-4(1%)在第一队列第28天和第56天显著增加TBUT(P<.05)。
- 第84天基于受试者报告的SANDE VAS评分,患者症状较基线降低46%。
- 基线DED症状更严重的患者比中度DED患者获得显著更大的缓解(P<.05)。
核心结论
- 据作者所知,这是SDP-4首次在临床试验中用于人体。
- SDP-4是一种首创的蛋白成分,以新型制剂为缓解严重DED症状提供了一种安全的多模式治疗方法。
研究设计与样本
- 探索性2期、12周和8周、序列队列、多中心、双盲、随机、赋形剂对照研究。
- 第一队列305例患者按1:1:1:1随机接受SDP-4(0.1%、1%、3% w/w)或赋形剂对照,每日两次(BID)。
- 第二队列151例患者按1:1随机接受1% w/w SDP-4(第一队列中表现最佳的制剂)或赋形剂对照,每日两次(BID)。
- 诊断为DED的患者于2019年4月至2021年5月在美国接受治疗。
- 第一队列受试者具有中重度基线症状,第二队列具有中度基线症状,以研究基线症状对SDP-4性能的影响。
主要发现
- SDP-4(1%)在第一队列第28天和第56天较赋形剂对照显著增加TBUT(P<.05)。
- 第84天基于受试者报告的SANDE VAS评分,患者症状较基线降低46%。
- 基线DED症状更严重的患者比中度DED患者获得显著更大的缓解(P<.05)。
- 所有治疗组耐受良好,总停药率为2.6%。
关键数值与推荐
- 关键体征和症状终点为研究期间TBUT和总SANDE评分(0-100视觉模拟量表)较基线的平均变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this study the safety and efficacy of silk-derived protein 4 (SDP-4), also known as amlisimod, eye drops against a vehicle control formulation in patients with moderate to severe dry eye disease (DED) was assessed. SDP-4 is a novel, naturally derived, anti-inflammatory wetting agent that enhances coating on the ocular surface. DESIGN: Exploratory Phase 2, 12- and 8-week, serial cohort, multicenter, double-masked, randomized, vehicle-controlled study. METHODS: In the first cohort (N = 305), patients were randomized 1:1:1:1 to SDP-4 (0.1%, 1%, 3% wt./wt.) or vehicle control and dosed 2 times per day (BID), while in the second cohort patients were randomized 1:1 with 1% wt./wt. SDP-4, the best performing formulation from the first cohort, or vehicle control BID (N = 151). Diagnosed DED patients were treated in the United States between April 2019 and May 2021. The first cohort of subjects had moderate to severe baseline symptoms, while the second cohort had moderate baseline symptoms to study the impact of baseline symptoms on SDP-4 performance. Key sign and symptom end points were mean change from baseline in TBUT and total SANDE score (0-100 visual analog scale) throughout the study. RESULTS: SDP-4 (1%) significantly increased TBUT vs the vehicle control (P < .05) at days 28 and 56 in the first cohort, and patient symptomatology from baseline was reduced by 46% based on subject reported SANDE VAS scores at day 84. Patients with more severe baseline DED symptoms experienced a significantly greater amount of relief than when compared to patients with moderate DED (P < .05). All treatment groups were well tolerated with a 2.6% total discontinuation rate. CONCLUSIONS: To the best of our knowledge, this was the first-in-human use of SDP-4 in a clinical trial. SDP-4 is a first-in-class protein ingredient that offers a safe and multi-modal treatment approach for alleviating severe DED symptoms within a novel formulation.
引用
- Lawrence BD, Karpecki PM, Infanger DW, et al. Silk-Derived Protein-4 Versus Vehicle Control in Treating Patients With Moderate to Severe Dry Eye Disease: A Randomized Clinical Trial. Am J Ophthalmol. 2024. PMID: 39218389. doi:10.1016/j.ajo.2024.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。